Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

Fig. 2

Overall survival. Overall survival Kaplan-Meier curves in all patients receiving only everolimus + lanreotide (n = 57) or sunitinib + lanreotide (n = 50), in patients with pNETs receiving everolimus + lanreotide (n = 27) or sunitinib + lanreotide (n = 28), and in patients with extrapancreatic neuroendocrine tumours receiving everolimus + lanreotide (n = 30) or sunitinib + lanreotide (n = 22)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us